Head and neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual
Citations Over TimeTop 1% of 2017 papers
Abstract
Answer questions and earn CME/CNE The recently released eighth edition of the American Joint Committee on Cancer (AJCC) Staging Manual, Head and Neck Section, introduces significant modifications from the prior seventh edition. This article details several of the most significant modifications, and the rationale for the revisions, to alert the reader to evolution of the field. The most significant update creates a separate staging algorithm for high-risk human papillomavirus-associated cancer of the oropharynx, distinguishing it from oropharyngeal cancer with other causes. Other modifications include: the reorganizing of skin cancer (other than melanoma and Merkel cell carcinoma) from a general chapter for the entire body to a head and neck-specific cutaneous malignancies chapter; division of cancer of the pharynx into 3 separate chapters; changes to the tumor (T) categories for oral cavity, skin, and nasopharynx; and the addition of extranodal cancer extension to lymph node category (N) in all but the viral-related cancers and mucosal melanoma. The Head and Neck Task Force worked with colleagues around the world to derive a staging system that reflects ongoing changes in head and neck oncology; it remains user friendly and consistent with the traditional tumor, lymph node, metastasis (TNM) staging paradigm. CA Cancer J Clin 2017;67:122-137. © 2017 American Cancer Society.
Related Papers
- → Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?(2018)5 cited
- Detection of Polyomavirus in Merkel cell carcinoma by immunohistochemistry: report of three cases.(2015)
- → Merkel cell carcinoma in an immunosuppressed patient(2017)4 cited
- → Prognostic biomarkers, pathogenic studies and treatment of Merkel Cell Carcinoma(2019)
- → Clinical, FDG-PET and Molecular Markers of Immune Checkpoint Inhibitor Response in Patients with Advanced Merkel Cell Carcinoma(2022)